6 results about "Stroke treatment" patented technology

This invention discloses a brain-targeting neutrophil membrane-encapsulated tanshinone IIa PLGA nanoparticle formulation, its preparation method, and its uses. The brain-targeting tanshinone IIa nanoparticle formulation, Neu-Tan-IIa@PLGA, is characterized by comprising a PLGA-loaded tanshinone IIa nanoparticle core (Tan-IIa@PLGA) and an outer neutrophil membrane coating. This invention effectively overcomes the problems of poor water solubility, low oral bioavailability, and difficulty in crossing the blood-brain barrier associated with tanshinone IIa. This invention provides a tanshinone IIa with strong targeting and high drug stability, enabling delivery to lesions in ischemic brain regions and improving the safety and efficacy of stroke treatment.

This invention provides a drug delivery system and its application based on brain microvascular endothelial cells, comprising stimulated brain microvascular endothelial cells, wherein the stimulation is performed by culturing in a culture system containing supernatant of brain microvascular endothelial cells cultured under glucose and oxygen deprivation. This invention solves the problems of targeting and timeliness in treating blood-brain barrier damage after ischemic stroke under current technologies. It can regulate the BBB while supporting its function and structure, maintaining and repairing BBB function after reperfusion, thus improving the prognosis of stroke treatment. The cell preparations in this invention are widely available and easily obtained, and can rapidly repair the blood-brain barrier. Furthermore, the cell preparations in this invention can target ischemic brain sites and can be administered via simple intravenous injection, facilitating clinical operation.

The present application provides a temperature-sensitive hydrogel system for intranasal delivery of mesenchymal stem cells and application, which comprises a poloxamer hydrogel as a carrier and mesenchymal stem cells loaded on the carrier; the poloxamer hydrogel as a carrier comprises poloxamer 407 and poloxamer 188, and further comprises at least one of epidermal growth factor and fibroblast growth factor. The present application solves the problems of low efficiency of mesenchymal stem cells into the brain and poor survival ability of mesenchymal stem cells in the nasal cavity in the treatment of ischemic stroke under the current technology, improves the accumulation and activity of mesenchymal stem cells in the lesion site, and improves the prognosis of stroke treatment. The cell preparation in the present application can target the brain ischemic site, and can be administered by non-invasive intranasal administration, avoiding the risk of secondary trauma caused by invasive administration.

This invention belongs to the field of biomedical technology and discloses a methylene blue-fingolimod prodrug based on hypochlorous acid activation, its preparation method, and its application. Fingolimod and methylene blue, which has hypochlorous acid scavenging and neuroprotective functions, are bonded together via a hypochlorous acid-sensitive thioether bridge. This design cleverly utilizes the abnormally high concentration of hypochlorous acid within the lesion as "molecular scissors," achieving precise activation of the prodrug at the target site and synergistic release of both drugs. This not only endows fingolimod with targeted noise reduction and enhanced efficacy but also simultaneously implements a combined attack of "detoxification" and "anti-inflammation," thereby more thoroughly breaking the damage cascade and providing a novel synergistic solution for stroke treatment.